Literature DB >> 15371829

Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen and Gleason score to predict prostate cancer stage.

Vassilis Poulakis1, Ulrich Witzsch, Rachelle De Vries, Volker Emmerlich, Michael Meves, Hans-Michael Altmannsberger, Eduard Becht.   

Abstract

PURPOSE: We developed an artificial neural network analysis (ANNA) to predict prostate cancer pathological stage more effectively than logistic regression (LR) based on the combined use of prostate specific antigen (PSA), biopsy Gleason score and pelvic coil magnetic resonance imaging (pMRI) in patients with clinically organ confined disease before radical prostatectomy.
MATERIALS AND METHODS: In 201 consecutive patients undergoing radical retropubic prostatectomy with pelvic lymphadenectomy the radiological-pathological correlation was evaluated using pMRI. Predictive variables were clinical TNM classification, preoperative serum PSA, biopsy Gleason score and pMRI findings. The predicted results were organ confined vs nonorgan confined disease and lymphatic vs no lymphatic involvement. The predicted ability of ANNA with several parameters in a set of 160 randomly selected test data was compared with that of LR and the Partin tables by area under the receiver operating characteristic curve analysis.
RESULTS: The overall accuracy of ANNA and LR was 88% and 91%, and 77% and 84% for nonorgan confined and lymphatic involvement, respectively. For nonorgan confined disease and lymph node involvement the area under the curve of ANNA (0.895 and 0.899) was significantly larger than that of LR and the Partin tables (0.722 and 0.751, and 0.750 and 0.733, respectively, p <0.05). Gleason score represented the most influential predictor (relative weight 2.05) of nonorgan confined disease, followed by pMRI findings (1.96), PSA (1.73) and clinical stage (0.89).
CONCLUSIONS: ANNA is superior to LR for accurately predicting pathological stage. The relative importance of pMRI findings and the usefulness of ANNA for predicting pathological stage in individuals must be confirmed in a prospective trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371829     DOI: 10.1097/01.ju.0000139881.04126.b6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

Review 1.  Artificial neural networks and prostate cancer--tools for diagnosis and management.

Authors:  Xinhai Hu; Henning Cammann; Hellmuth-A Meyer; Kurt Miller; Klaus Jung; Carsten Stephan
Journal:  Nat Rev Urol       Date:  2013-02-12       Impact factor: 14.432

2.  Role of pelvic lymph node dissection in prostate cancer treatment.

Authors:  Jae Young Joung; In-Chang Cho; Kang Hyun Lee
Journal:  Korean J Urol       Date:  2011-07-24

3.  Final Gleason score prediction using discriminant analysis and support vector machine based on preoperative multiparametric MR imaging of prostate cancer at 3T.

Authors:  Fusun Citak-Er; Metin Vural; Omer Acar; Tarik Esen; Aslihan Onay; Esin Ozturk-Isik
Journal:  Biomed Res Int       Date:  2014-12-02       Impact factor: 3.411

Review 4.  THE ROLE OF LYMPHADENECTOMY IN PROSTATE CANCER PATIENTS.

Authors:  Dean Markić; Romano Oguić; Kristian Krpina; Ivan Vukelić; Gordana Đorđević; Iva Žuža; Josip Španjol
Journal:  Acta Clin Croat       Date:  2019-11       Impact factor: 0.780

5.  Prediction of biochemical failure in localized carcinoma of prostate after radical prostatectomy by neuro-fuzzy.

Authors:  Neeraj Kumar Goyal; Abhay Kumar; Rajiba L Acharya; Udai Shankar Dwivedi; Sameer Trivedi; Pratap Bahadur Singh; T N Singh
Journal:  Indian J Urol       Date:  2007-01

6.  A systematic review of the applications of Expert Systems (ES) and machine learning (ML) in clinical urology.

Authors:  Hesham Salem; Daniele Soria; Jonathan N Lund; Amir Awwad
Journal:  BMC Med Inform Decis Mak       Date:  2021-07-22       Impact factor: 2.796

7.  Impact of intraoperative MRI/TRUS fusion on dosimetric parameters in cT3a prostate cancer patients treated with high-dose-rate real-time brachytherapy.

Authors:  Alfonso Gomez-Iturriaga; Juanita Crook; Francisco Casquero; Claudia Carvajal; Arantxa Urresola; Begoña Canteli; Ana Ezquerro; Eduardo Hortelano; Jon Cacicedo; Jose Maria Espinosa; Fernando Perez; Pablo Minguez; Pedro Bilbao
Journal:  J Contemp Brachytherapy       Date:  2014-06-09

8.  An imaging-based approach predicts clinical outcomes in prostate cancer through a novel support vector machine classification.

Authors:  Yu-Dong Zhang; Jing Wang; Chen-Jiang Wu; Mei-Ling Bao; Hai Li; Xiao-Ning Wang; Jun Tao; Hai-Bin Shi
Journal:  Oncotarget       Date:  2016-11-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.